Sol-Gel net loss narrows to $3.7 million on lower R&D spending
Sol-Gel Technologies (NASDAQ:SLGL) reported a narrowed net loss for the first quarter of 2026, driven by a sharp reduction in research and development expenses as the clinical-stage biotechnology firm solidified its financing footprint.

_1408240_640x360_2501606467654-640x360.webp&w=3840&q=75)
_1408185_640x360_2501570115579-640x360.webp&w=3840&q=75)

_1408149_640x360_2501562435910-640x360.webp&w=3840&q=75)
_1408136_640x360_2501558339802-640x360.webp&w=3840&q=75)
_1408124_640x360_2501557827933-640x360.webp&w=3840&q=75)
_1408121_640x360_2501558339732-640x360.webp&w=3840&q=75)

_1408096_640x360_2501556803815-640x360.webp&w=3840&q=75)

